Gynecologic oncologyAgedFemaleHumansMiddle AgedCarcinoma
First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
Yun Wang, Els Van Nieuwenhuysen, Mona-Elisabeth Revheim, Christophe M Deroose, Ane Gerda Zahl Eriksson, Brynhildur Eyjolfsdottir, Toon Van Gorp, Thaïs Baert, Anne-Kirsti Aksnes, Kari Myren, Ignace Vergote, Øyvind S Bruland
Published: 202610.1016/j.ygyno.2025.11.018
Abstract
OBJECTIVE: The aim of this Phase 1 study was to evaluate safety and tolerability of the alpha emitting therapy 224Ra-labeled microparticles (Radspherin®) and to establish the recommended dose for further development. METHODS: The study was conducted…
Preview only. Read the full abstract at the source